Regional West Health Services says a Scottsbluff psychiatry service introduced Spravato for adults after two or more antidepressants did not provide desired results.
New option reported in Scottsbluff
Regional West Health Services reports that a psychiatry service in Scottsbluff has introduced Spravato, expanding treatment options in western Nebraska. The source describes Spravato as an FDA-approved nasal spray.
The announcement concerns adults who have tried two or more antidepressants without getting the desired results, according to Regional West Health Services. The source identifies this group in describing the new option for treatment-resistant depression.
Monitored treatment sessions
Regional West Health Services says Spravato is given in monitored sessions lasting two hours. The source says the sessions occur over an eight-week period.
The announcement does not provide further details about how many sessions are involved, what happens during monitoring, or how patients are assessed for this option. It also does not report patient outcomes.
What the source says about access
According to Regional West Health Services, the introduction of Spravato broadens available treatment options in western Nebraska. The source specifically places the service in Scottsbluff.
The announcement does not state whether coverage, referral requirements, scheduling availability, costs, or transportation support are available. It also does not describe whether people outside the Scottsbluff area can use the service.
Treatment context
Regional West Health Services describes Spravato as an option for adults who have already tried at least two antidepressants without the desired results. The source does not compare Spravato with other depression treatments or say which patients may receive it.
The announcement also does not provide information about individual treatment decisions. Its stated focus is the introduction of a monitored, eight-week Spravato option in western Nebraska.
What this means for Nebraska patients
For people looking for treatment locally, this update identifies an additional reported option in Scottsbluff; the directory lists 11 published clinics in Nebraska. The source indicates that the option is intended for adults who have tried two or more antidepressants without desired results and involves monitored sessions over eight weeks.
This is general information, not medical advice.
More Nebraska reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.